

## Pharmfax Lights

Welcome to the January 2021 edition of Pharmfax Lights which highlights recent medicine traffic light classifications in Leeds. For definitions of the different classifications please see the foot of this page. The following Traffic Light classification were ratified by the Leeds Area Prescribing Committee on 16.12.2020

### USEFUL LINKS

For full details of traffic light classifications and the traffic light list:

<http://nww.lhp.leedsth.nhs.uk/common/guidelines>

Leeds Formulary: <http://www.leedsformulary.nhs.uk>

### Secondary Care Requests for Primary Care Prescribing

Occasionally, a secondary care clinician may ask a GP to prescribe a medicine which not on the Leeds Formulary, or is not on it for that particular indication. The Leeds Area Prescribing Committee has produced some guidance for GPs to manage these situations. The process to follow in these circumstances can be found [here](#)

### COVID-19 MEDICINES INFORMATION

[Link to Medicines information /Leeds CCG Website](#)

### Black Light classification

- Cannabidiol oral liquid (100mg/ml) (Epidyolex) – for treatment of all non-NICE, non-commissioned indications

### **Black Light - Not Yet Reviewed (in Leeds)**

- Filgotinib maleate F/C Tablets (100 & 200mg) (Jyseleca) for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). May be used as monotherapy or in combination with methotrexate (MTX).
- Lauromacrogol 400 Solution for Injection (2.5, 5, 10, 20 & 30 mg/ml) (Aethoxysklerol) for the treatment of sclerotherapy of varicose veins of the lower extremities.

### **Amber Level 1 - standard guidance**

#### [LINK TO AL1 STANDARD GUIDANCE](#)

- Ticagrelor tablets (90mg) (Brilique) For use as antiplatelet therapy for percutaneous coronary intervention (PCI) for adult patients with aspirin allergy where desensitisation has been unsuccessful or is not recommended

### **Amber Level 1 additional information**

Glycopyrronium Bromide oral: Amber Drug Guidance for the treatment of hypersalivation for adults and paediatrics ([Link](#))

Amber Level 1 guidance for the treatment of epilepsy in adults ([Link](#))

### **Amber Level 2 – standard guidance**

#### [LINK TO AL2 STANDARD GUIDANCE](#)

- Melatonin 2mg MR tablets (Circadin) - For the prevention of cluster headaches (note melatonin has different TLL classifications for different indications see)

## Amber Level 2 additional information

Valaciclovir - Amber Drug Guidance for the treatment of Herpes Simplex Virus (HSV) Encephalitis in Paediatrics ([Link](#))

Rupatadine fumarate: Amber Drug Guidance for the treatment of chronic urticaria/angioedema ([Link](#))

Amber Level 2 guidance for the treatment of epilepsy in children ([Link](#))

Taurine: Amber Drug Guidance for the Treatment of Cystic Fibrosis Related Liver Disease ([Link](#))

## Amber Level 3

Danazol - Amber Drugs Guidance for the treatment of Hereditary Angioedema (HAE) ([Link](#))

Penicillamine: Guidance for the Treatment of Rheumatology in Adults ([Link](#))

Modafinil: Amber Drug Guidance for the treatment of Adults with: ([Link](#))

1. Narcolepsy
2. Fatigue in patients with Multiple Sclerosis
3. Residual sleepiness associated with Obstructive Sleep Apnoea & Idiopathic Hyper-somnolence -

Mepacrine: Amber Drug Guidance for the treatment of Systemic Lupus Erythematosus (SLE) and dermatological conditions ([Link](#))

Sulfasalazine: Amber Drug Guidance for the treatment of juvenile idiopathic arthritis ([Link](#))

Hydroxycarbamide: Amber Drug Guidance for the treatment of Psoriasis in adults ([Link](#))

Hydroxycarbamide: Amber Drug Guidance for the treatment of Polycythaemia, Thrombocythaemia, Chronic Myeloid Leukaemia (CML) ([Link](#))

## Grey classification

- Naldemedine for the treatment of opioid induced constipation  
Note: to be prescribed in line with NICE TA651 and local opioid induced constipation guideline (currently under review)

### **Green classification**

- Calcitriol capsules - 0.25 & 0.5 micrograms (Rocaltrol) Indicated for:
  - correction of the abnormalities of calcium and phosphate metabolism in patients with renal osteodystrophy.
  - treatment of established post-menopausal osteoporosis.
- Dexamethasone 0.1% drops preservative free (Eythalm®) for the treatment of non-infectious inflammatory eye conditions

### **Red classification**

- Acetylcholine Chloride Powder and Solvent for Solution for Intraocular Irrigation (20mg)(Miochol-E) - for coronary function tests
- Avatrombopag 20mg tablets (Doptelet) - for the treatment of severe thrombocytopenia in patients with chronic liver disease needing a planned invasive procedure for adults and children
- Berotralstat 150mg capsules (ULM) - to prevent hereditary angioedema (ULM)
- Dabrafenib capsules and trametanib tablets (Dabrafenib brand is Tafinlar®/Trametanib brand is Mekinist®) - for anaplastic thyroid cancer
- Obinutuzumab solution for infusion (100mg) (Gazyvaro) - for the treatment of systemic lupus erythematosus
- Rivaroxaban tablets (2.5mg) (Xarelto) - for use as antiplatelet therapy for percutaneous coronary intervention (PCI) for adult patients with aspirin allergy where desensitisation has been unsuccessful or is not recommended
- Ustekinumab intravenous infusion and subcutaneous injection pre-filled syringe (Stelara®) - for the treatment of Ulcerative Colitis
- Venetoclax tablets (Venclyxto®) for the treatment of NPM1 mutated acute myeloid leukaemia

### Red classification - commissioned by NHSE

- Atezolizumab infusion (Tecentriq®) for the treatment of breast cancer
- Atezolizumab infusion in combination with bevacizumab ( ) infusion (Atezolizumab infusion brand is Tecentriq® / Bevacizumab infusion brand is Avastin®) for the treatment of adult patients with unresectable hepatocellular carcinoma who have received no prior systemic therapy (EAMS)
- Brentuximab 50 mg powder for concentrate for solution for infusion - for the treatment of untreated systemic anaplastic large cell lymphoma
- Dexrazoxane injection (Cardioxane) - for preventing cardiotoxicity in children and young people (under 25 years) receiving high-dose anthracyclines or related drugs for the treatment of cancer
- Eltrombopag 25mg, 50mg & 75mg tablets (Revolade®) for use as bridging therapy to stem cell transplant in adults and children
- Gilteritinib f/c tablets (40mg) (Xospata) for treatment of acute myeloid leukaemia
- Ivacaftor tablets, granules (Kalydeco®) for the treatment of Cystic fibrosis R117H mutation
- Nivolumab infusion (Opdivo®) for use as monotherapy treatment of adults with unresectable advanced, recurrent or metastatic oesophageal, squamous cell carcinoma (OSCC) after one prior fluoropyrimidine and platinum-based chemotherapy
- Obinutuzumab solution for infusion with bendamustine (Obinutuzumab brand is Gazyvaro®) for the treatment of follicular lymphoma after rituximab
- Paclitaxel Albumin infusion (Abraxane®) for the treatment of Breast Cancer (ULU)
- Rituximab injection for the treatment of Systemic Lupus Erythematosos (SLE)
- Treosulfan powder for solution for infusion (5g) (Trecondi) for the treatment of malignant disease before allogeneic stem cell transplant
- Turoctocog alfa pegol (pegylated human coagulation factor VIII (rDNA) injection (Esperoct®) for the treatment of haemophilia A

### Dual classification

- Urea based products for disorders of keratinisation over the heels which causes significant pain and risks poor wound healing/ulceration
  - Grey classification for Diabetic patients on recommendation of podiatry specialist
  - Amber level 1 standard template only for patients with disorders of keratinisation over the heels which causes significant pain and risks poor wound healing/ulceration on the advice of a dermatology or podiatry specialist
- Semaglutide tablets (3, 7 & 14mg) (Rybelsus) for the treatment of insufficiently controlled type 2 diabetes mellitus
  - Green if used on its own
  - Amber Level 1 if used with insulin

### **Dual classification cont/d**

- Sumatriptan 3mg/0.5ml solution for injection in pre-filled pen for the treatment of Acute relief of migraine attacks, with or without aura
  - Green for adults
  - Amber level 1 for the treatment of paediatric migraine (line extension)

### **Guidance, Policies and Pathways**

- Clozapine: Information for Primary Care ([Link](#))
- Erectile Dysfunction Management Using PDE5 Inhibitors ([Link](#))
- Impaired Liver Function - Prescribing at the end of Life in the community ([Link](#))
- Renal Failure - Prescribing at the End of Life in the ([Link](#))
- Policy on Insulin Devices and Needles for Primary ([Link](#))
- Influenza Prevention and Treatment in Primary Care ([Link](#))
- A guide to managing heart failure: An Integrated approach ([Link](#))
- Top 10 tips when prescribing stoma supplies ([Link](#))
- Shared Management of Medicines (SMOM) Formulary Change Request Form ([Link](#))

## Leeds Traffic Light Classifications - Definitions

**GREEN DRUGS:** Medicines which are appropriate for initiation and ongoing prescribing in both primary and secondary care. Due to the extensive number of Green Drugs, there is currently not a list of these medicines.

**AMBER DRUGS:** These are medicines which are recommended or initiated by a specialist, but can then be prescribed by primary care physicians. Amber Drugs will be classified under three different headings:-

- Amber Drugs recommended by a specialist (Amber Level 1)
- Amber Drugs initiated by a specialist (Amber Level 2)
- Amber Drugs with specialist initiation and ongoing monitoring requirements (Amber Level 3)

**RED DRUGS:** Medicines for hospital use only. Primary care prescriber initiation or continuation of treatment is not recommended.

**RED DRUGS – commissioned by NHSE:** Medicines for hospital use only commissioned by NHSE. Primary care prescriber initiation or continuation of treatment is not recommended.

**GREY DRUGS:** are locally agreed medicines which are recommended for specific indications but not others. The Grey List outlines circumstances in which specific prescribing is appropriate. The Grey List is intended to support good prescribing and help prescribers make balanced decisions. .

**BLACK LIGHT DRUGS:** These drugs are not recommended for prescribing within the Leeds health economy. All new drugs will be assumed Black Light until they have been through the appropriate approval process.

**BLACK LIGHT - (NOT YET REVIEWED)** These drugs are newly licensed and will not receive a review unless requested by a clinician in Leeds

**DEVICES:** The Leeds Area Prescribing Committee will usually only consider traffic light classifications for devices that facilitate medicines use or are used in a "medicines like way". For devices that are listed in the drug tariff but do not meet this definition prescribing is at the discretion of the prescriber. Please note that devices do not go through the same process as medicines before inclusion in the drug tariff, therefore listing in the drug tariff does not necessarily mean the device is evidence-based and cost effective.

## Next Pharmfax Lights Bulletin : February 2021